Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy.
Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy.
复制标题
PD-1/L1抑制剂在乳腺癌免疫治疗中的临床研究进展
DOI：
10.3389/fonc.2021.724424
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Cui J
中科院分区：
文献类型：
--
作者：
Chen F;Chen N;Gao Y;Jia L;Lyu Z;Cui J
乳腺癌是全世界妇女健康的主要杀手。虽然乳腺癌被认为与其他实体瘤相比具有较低的免疫原性，但联合治疗能够提高肿瘤的免疫原性并使乳腺癌细胞对免疫治疗敏感。以免疫检查点抑制剂（immune checkpoint inhibitors，ICI）为代表的免疫治疗已在乳腺癌领域进行了大量探索，包括早期和晚期疾病。针对三阴性乳腺癌（TNBC）的免疫治疗研究最多，PD-L1抑制剂atezolizumab联合nab-紫杉醇已用于TNBC的一线治疗。人类表皮生长因子受体阳性和激素受体阳性乳腺癌的免疫数据也在积累。本文综述了ICI或含ICI治疗不同类型和阶段乳腺癌的临床试验数据。
Breast cancer is a major killer of women’s health worldwide. While breast cancer is thought to have lower immunogenicity compared with other solid tumors, combination therapy is able to improve the immunogenicity of the tumor and sensitize breast cancer cells to immunotherapy. Immunotherapy represented by immune checkpoint inhibitors (ICIs) has been largely explored in the field of breast cancer, including both early and advanced disease. Immunotherapy for triple-negative breast cancer (TNBC) has been the most studied, and the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel has been used in the first-line treatment of TNBC. Immunotherapeutic data for human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer are also accumulating. This review summarizes the clinical trial data of ICIs or ICI-containing therapies in different types and stages of breast cancer.
登录
查看更多内容
影响因子：
5.8
作者：
Chia, Stephen;Bedard, Phillipe L.;Seymour, Lesley
通讯作者：
Seymour, Lesley
影响因子：
32.4
作者：
Ebert, Peter J. R.;Cheung, Jeanne;Mellman, Ira
通讯作者：
Mellman, Ira
影响因子：
45.3
作者：
Adams, Sylvia;Gray, Robert J.;Badve, Sunil S.
通讯作者：
Badve, Sunil S.
影响因子：
45.3
作者：
Alva, Ajjai S.;Mangat, Pam K.;Schilsky, Richard L.
通讯作者：
Schilsky, Richard L.
影响因子：
7.3
作者：
Corraliza-Gorjón I;Somovilla-Crespo B;Santamaria S;Garcia-Sanz JA;Kremer L
通讯作者：
Kremer L